乙肝病毒基因型与抗病毒治疗应答的相关性研究

Influence of HBV Genotypes on Response to Antivirotic Therapy

目的 :旨在探讨乙肝病毒基因型对α 干扰素抗病毒治疗应答的影响。方法 :12 6例慢性HBVDNA阳性患者中B基因型 3 8例 ,C基因型 69例 ,B +C基因型 19例。所有患者均采用α 干扰素 3 0 0万单位 ,肌肉注射 ,每周 3次 ,共 2 4周。结果 :B基因型起始应答率 (81 6% )明显高于C基因型 (3 7 7% )及B +C基因型 (4 2 1% ) ,而持续应答率为 42 1% ,亦明显高于基因型C (14 5 % )及基因型B +C (15 8% ) (均P <0 0 0 1)。结论 :B基因型抗病毒治疗应答率高 。

Objective: To evaluate the influence of HBV genotypes on response to recombinant-interferon-alpha(r-IFN-α)therapy in chronic HBV DNA positive patients.Methods: Of the 126 patients, 38 were genotype B, 69 were genotype C, 19 were mixed genotype B+C, all the patients were treated with 3 million units of IFN-α, 3 times a week for 6 months.Results:Initial response(IR) was significantly better in patients with genotype B(81.6%)infections than in patients with genotype C(37.7%) and genotype B+C (42.1%)( P <0.005). Sustained response(SR) was observed in 42.1% for genotype B, 14.5% for genotype C and 15.8% for genotype B+C; significant differences were found between genotype B and genotype C ( P <0.001),and between genotype B and genotype B+C( P< 0.001).Conclusion:Genotype B was associated with sustained response to IFN-α therapy. These data indicate that HBV genotyping may have prognostic relevance in the response to IFN-α therapy in patients with chronic HBV infection.